Archives of Endocrinology and Metabolism (Oct 2020)

The polymorphic inheritance of DIO2 rs225014 may predict body weight variation after Graves’ disease treatment

  • Ana Paula Comarella,
  • Danilo Vilagellin,
  • Natassia Elena Bufalo,
  • Jessica Ferreira Euflauzino,
  • Elisangela de Souza Teixeira,
  • Ana Beatriz Pinotti Pedro Miklos,
  • Roberto Bernardo dos Santos,
  • João H. Romaldini,
  • Laura S. Ward

DOI
https://doi.org/10.20945/2359-3997000000295
Journal volume & issue
Vol. 64, no. 6
pp. 787 – 795

Abstract

Read online

ABSTRACT Objective: We aimed to investigate the role of DIO2 polymorphisms rs225014 and rs12885300 in Graves’ disease patients, mainly for controlling body weight following treatment. Subjects and methods: We genotyped 280 GD patients by the time of diagnosis and 297 healthy control individuals using a TaqMan SNP Genotyping technique. We followed up 141 patients for 18.94 ± 6.59 months after treatment. Results: There was no relationship between the investigated polymorphisms with susceptibility to GD and gain or loss of weight after GD treatment. However, the polymorphic inheritance (CC+CT genotype) of DIO2 rs225014 was associated with a lower body weight variation after GD treatment (4.26 ± 6.25 kg) when compared to wild type TT genotype (6.34 ± 7.26 kg; p = 0.0456 adjusted for the follow-up time). This data was confirmed by a multivariate analysis (p = 0.0138) along with a longer follow-up period (p = 0.0228), older age (p = 0.0306), treatment with radioiodine (p-value = 0.0080) and polymorphic inheritance of DIO2 rs12885300 (p = 0.0306). Conclusion: We suggest that DIO2 rs225014 genotyping may have an auxiliary role in predicting the post-treatment weight behavior of GD patients.

Keywords